biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Fabry

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Feb 23, 2023 3:46pm

67 Views

Post# 35301779

RE:Fabry

@BiotechAnalysst

 				BofA $SGMO Clinical benefit seen with sustained ERT withdrawal positive clinical readout of phase 1/2 Fabry program with patients showing sustained alpha-galactosidase A activity #Fabry program could be an opportunity to be #best in #class with patients continuing to withdraw ERT